Search

Introduction: Multiple evanescent white dot syndrome (MEWDS) is a rare, usually unilateral, retinal disease associated with transient loss of vision. Its pathogenesis remains elusive. The purpose of this study was to determine the spatial location of the lesions in the neurosensory retina of a patient with MEWDS, using a new technology, i.e. "en face" optical coherence tomography ("en face" OCT)., Methods: A 21-year-old woman presenting with bilateral MEWDS underwent Cirrus(®) OCT with advanced "en face" reconstructions of the various retinal layers and inner choroid, fluorescein angiography, and infracyanine green angiography (ICGA)., Results: During the acute stage of MEWDS, advanced "en face" visualization mode of the IS/OS photoreceptor junction and the inner choroid showed areas of strong signal attenuation, forming a spot pattern identical to that of the hypofluorescent IGCA dots. One month later, visual acuity returned to 20/25 in both eyes and the reflectivity map of the IS/OS junction and inner choroid displayed no areas of signal attenuation., Conclusion: "En face" OCT is a new, noninvasive technology, capable of visualizing specific attenuation of the IS/OS junction in MEWDS, which form a spot pattern identical to those revealed by ICGA., (Copyright © 2013 Elsevier Masson SAS. All rights reserved.)

Purpose: Silicone oil must be removed from the eye to avoid late complications after the surgical management of proliferative vitreoretinopathy (PVR). Macular pucker, frequently observed after retinal detachment surgery, is responsible for visual impairment. The safety of a procedure combining epimacular membrane peeling and silicone oil removal was retrospectively evaluated., Methods: Fourteen eyes that had previously undergone vitrectomy and silicone oil tamponade for rhegmatogenous retinal detachment with severe PVR, penetrating or blunt trauma, and intraocular foreign bodies were included. Silicone oil tamponade was maintained for a mean period of 30 weeks (range, 12-108 weeks). The removal of silicone oil was combined with the peeling of an epimacular membrane., Results: Mean follow-up after silicone oil removal was 86 weeks (range, 13-234 weeks). The final retinal reattachment rate was 78%. Macular pucker recurred in one eye after a 24-month period. Best-corrected visual acuity improved two lines or more in eight eyes (57%) and reached 20/200 or better in eight eyes (57%) at last follow-up., Conclusion: Macular pucker dissection and silicone oil removal can be safely combined. This single procedure can obviate the need for further surgery in eyes that have already undergone multiple operations and allows good visual recovery.

Background: Until recently, only two options were available for the treatment of choroidal neovascularisation (CNV) associated with age related macular degeneration (AMD)—thermal laser photocoagulation and photodynamic therapy with verteporfin (PDT-V). However, new treatments for CNV are in development, and data from phase III clinical trials of some of these pharmacological interventions are now available. In light of these new data, expert guidance is required to enable retina specialists with expertise in the management of AMD to select and use the most appropriate therapies for the treatment of neovascular AMD. Methods: Consensus from a round table of European retina specialists was obtained based on best available scientific data. Data rated at evidence levels 1 and 2 were evaluated for laser photocoagulation, PDT-V, pegaptanib sodium, and ranibizumab. Other treatments discussed are anecortave acetate, triamcinolone acetonide, bevacizumab, rostaporfin (SnET2), squalamine, and transpupillary thermotherapy. Results: PDT-V is currently recommended for subfoveal lesions with predominantly classic CNV, or with occult with no classic CNV with evidence of recent disease progression and a lesion size ⩽4 Macular Photocoagulation Study (MPS) disc areas (DA). The new classes of anti-angiogenic agents—namely, pegaptanib sodium and ranibizumab (the latter when peer reviewed phase III data become available) are recommended for subfoveal lesions with any proportion of classic CNV or occult with no classic CNV. For juxtafoveal classic CNV, PDT-V or anti-angiogenic therapy should be considered if the new vessels are so close to the fovea that laser photocoagulation would almost certainly extend under the centre of the foveal avascular zone. For all other well demarcated juxtafoveal lesions and for extrafoveal classic lesions, laser photocoagulation remains the standard treatment. Therapy should be undertaken within 1 week of the fluorescein angiogram on which the clinical decision to treat is based. At each follow up, fluorescein angiography should be performed and best corrected visual acuity measured as a minimum requirement. Conclusions: These recommendations provide evidence based guidance for the choice and use of non-surgical therapies for the management of neovascular AMD. Revisions of the recommendations may be required as new data become available. [ABSTRACT FROM AUTHOR]